checkAd
    Startseite > Aktien > OptiNose > Nachrichten
    OptiNose Aktie
    1,1700
     
    EUR
    -1,68 %
    -0,0200 EUR
    Letzter Kurs 17.05.24 Tradegate
    1,1500
     
    EUR
    1.440 STK
    Geldkurs 17.05.24
    1,1800
     
    EUR
    1.400 STK
    Briefkurs 17.05.24
    ISIN: US68404V1008 · WKN: A2H5PR · SYM: 0OP · USA

    Neueste Nachrichten

    Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
    17.05.24 · globenewswire · OptiNose
    Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
    14.05.24 · globenewswire · OptiNose
    Optinose Announces Reporting Date for First Quarter 2024 Financial Results
    10.05.24 · globenewswire · OptiNose
    Optinose Announces $55 Million Registered Direct Offering
    09.05.24 · globenewswire · OptiNose
    Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
    25.04.24 · globenewswire · OptiNose
    Optinose to Present at the Needham Virtual Healthcare Conference
    04.04.24 · globenewswire · OptiNose
    XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
    15.03.24 · globenewswire · OptiNose
    Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
    07.03.24 · globenewswire · OptiNose
    Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
    29.02.24 · globenewswire · OptiNose
    Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
    18.01.24 · globenewswire · OptiNose
    Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
    22.11.23 · globenewswire · OptiNose
    Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
    09.11.23 · globenewswire · OptiNose